Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MIRA Pharmaceuticals, Inc. - Common Stock (NQ: MIRA ) 1.150 -0.020 (-1.71%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about MIRA Pharmaceuticals, Inc. - Common Stock < Previous 1 2 3 4 Next > Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game October 03, 2024 Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game Via News Direct Topics Cannabis Exposures Cannabis Why Mira Shares Are Trading Higher Today September 27, 2024 MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here's what you need... Via Benzinga MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 September 27, 2024 Via ACCESSWIRE MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 September 19, 2024 MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 Via News Direct MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 September 18, 2024 Via ACCESSWIRE Peering Into Mira Pharmaceuticals's Recent Short Interest September 11, 2024 Via Benzinga MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study August 26, 2024 Via ACCESSWIRE (MIRA) - Analyzing Mira Pharmaceuticals's Short Interest July 26, 2024 Via Benzinga MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA September 11, 2024 Via ACCESSWIRE The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End August 27, 2024 The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End Via News Direct MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies August 26, 2024 MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain threshold normalization in rats, positioning it as a potential breakthrough for... Via Benzinga Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket August 26, 2024 Via Benzinga MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action July 25, 2024 Via ACCESSWIRE Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday August 26, 2024 Via Benzinga MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End August 19, 2024 Via ACCESSWIRE MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024 August 13, 2024 MIRA stock results show that Mira Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor August 12, 2024 Via ACCESSWIRE Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket August 05, 2024 Via Benzinga EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank? August 01, 2024 A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others. Via Benzinga MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year July 29, 2024 MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year Via News Direct Topics Cannabis Exposures Cannabis Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data July 25, 2024 MIRA Pharmaceuticals stock surged on Thursday following new preclinical data on Ketamir-2, MIRA's novel oral ketamine analog, highlighting its unique selectivity and favorable safety profile for... Via Benzinga Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 23, 2024 Via Benzinga Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today? July 23, 2024 Mira Pharmaceuticals stock is falling on Tuesday but that's only after shares of MIRA underwent a massive rally on Monday. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 23, 2024 Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning! Via InvestorPlace Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket July 23, 2024 Via Benzinga S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher July 22, 2024 Via Benzinga Topics Stocks Exposures US Equities Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 22, 2024 Via Benzinga Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? July 22, 2024 MIRA Pharmaceuticals stock is up on Monday after the company posted results from a pre-clinical trial of its novel oral ketamine analog. Via InvestorPlace Dow Edges Lower; Verizon Shares Fall After Q2 Results July 22, 2024 Via Benzinga Topics Stocks Exposures US Equities Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders July 22, 2024 MIRA Pharmaceuticals reveals preclinical data for its novel oral ketamine analog, Ketamir-2, targeting neurological and neuropsychiatric disorders. With superior oral absorption and efficacy, Ketamir-2... Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.